Risk of cancer in patients using glucose-lowering agents: a nationwide cohort study of 3.6 million people

Charlotte Andersson,1 Allan Vaag,2 Christian Selmer,1 Michelle Schmiegelow,1 Rikke Sørensen,1 Jesper Lindhardsen,1 Gunnar H Gislason,1 Lars Køber,3 Christian Torp-Pedersen 1,4

ABSTRACT

Objectives: To study the association between exposures to glucose-lowering therapy and risk of cancer using the nationwide administrative registers in Denmark.

Design: Nationwide cohort study.

Setting: All hospitals in Denmark.

Participants: All individuals aged ≥35 years in 1998–2009 who were naive to glucose-lowering treatment and had no history of cancer. Primary measures outcomes: first cancer diagnosis between 1998 and 2009. The RR of cancer as dependent on exposure to individual glucose-lowering agents was assessed by multivariable Poisson regression models.

Results: Of 159 894 patients that initiated treatment with glucose-lowering agents, 12 789 developed cancer, incidence rate 17.4/1000 person-years. Of the remaining 3 447 904 individuals not using glucose-lowering agents, 293 878 developed cancer, incidence rate 7.9/1000 person-years. Use of different types of glucose-lowering agents including human insulin, insulin analogues, as well as sulfonylureas were associated with a quantitatively similar and significantly increased RR of cancer of 1.2–1.3 compared with unexposed individuals after only 6–12 months of therapy for most agents.

Conclusions: Use of most glucose-lowering agents including sulfonylureas was associated with a comparable increased risk of cancer shortly after initiation of treatment and subsequently a decline to the risk of the background population. This suggests that the relation is not causal.

INTRODUCTION

Recent epidemiological studies have reported a positive relationship between cancer and use of insulin, which has caused major safety concerns among patients as well as clinicians.1 Insulin is known to possess affinity for the insulin-like growth factor (IGF)-1 receptor, which enhances cell growth and increases resistance to apoptosis.2 3 Receptor binding studies demonstrated that different types of insulin analogues exhibit different affinities for the IGF-1 receptor compared with native human insulin, and studies have reported colorectal, breast and prostate cell lines to proliferate in response to exposure to some types of insulin analogues.
but not to human insulin.\textsuperscript{4–6} To this end, some observational studies indicated that use of insulin glargine, being the approved insulin analogue with the putative highest affinity for the IGF-1 receptor, is associated with a disproportionately increased RR of cancer compared with human insulin.\textsuperscript{1,7–9}

Besides insulin, other features associated with diabetes such as obesity and hyperglycaemia \textit{per se} are known risk factors of cancer with increased oxidative stress and DNA damage representing suspected causal mechanisms.\textsuperscript{10} Indeed, caution is warranted concluding from observational and non-randomised studies that treatment with insulin or its analogues increases risk of cancer. Recent data have demonstrated that the RR of cancer fluctuates over time, being highest at time of diagnosis when treatment is initiated, supporting the notion of a potential observational bias.\textsuperscript{11} While much attention has been on the potential impact of insulin and insulin analogues on the risk of cancer, little is known about the time relationship between initiation of glucose-lowering treatment and cancer diagnosis for individual glucose-lowering agents including oral glucose-lowering agents. We therefore examined the association between risk of incident cancer and exposure to the most used individual insulin agents (insulin glargine, insulin lispro, insulin aspart, insulin detemir and human insulin), as well as oral glucose-lowering agents (sulfonylureas (SU), metformin and thiazolidinediones) using the entire Danish population.

**METHODS**

**Registers**

The public financed healthcare system provides a unique possibility to hold complete and nationwide registers on a variety of variables in Denmark. We used four of these registers to obtain data for the present study. The \textit{Central Population Register} includes information on all individuals living in Denmark. All individuals are registered with date of birth and gender. The \textit{Danish National Patient Register} includes information on dates and causes of hospitalisations in Denmark since 1978. All hospitalisations are registered according to the International Classification of Diseases (ICD) system. The \textit{Danish National Prescription Register} holds data on every dispensed prescription in Denmark since 1995. Dispensed drugs are registered by the Anatomical Therapeutic Classification (ATC) system with information on date of dispensing and amount dispensed available. Because of partial reimbursement of drug expenses, the accuracy of the register is very good.\textsuperscript{12} In the \textit{National Causes of Deaths Register}, all deaths occurring in Denmark are registered within 2 weeks after occurrence.

**Study population**

We identified all Danish individuals who had not claimed a prescription for glucose-lowering agents in 1995—1997 and who had never had cancer, as deemed by any cancer diagnoses in 1978—1997, and who were \textgeq35 years old during follow-up. Exposure to the following glucose-lowering agents was identified: insulin glargine (Lantus\textsuperscript{®} ATC-code A10AE04), insulin lispro (Humalog\textsuperscript{®} ATC-code A10AB04, Humalog Mix\textsuperscript{®} A10AD04), human insulin (Actrapid\textsuperscript{®} ATC-code A10AB01, Insulatard\textsuperscript{®} ATC-code A10AC01, Mixtard\textsuperscript{®} ATC-code A10AD01), insulin aspart (NovoRapid\textsuperscript{®} ATC-code A10AB05, NovoMix\textsuperscript{®} ATC-code A10AD05), insulin detemir (Levemir\textsuperscript{®} ATC-code A10AE05), metformin (ATC-code A10BA02), SU (ATC-code A10BB01, A10BB03, A10BB07, A10BB09, A10BB12) and thiazolidinediones (ATC-code A10BG02, A10BG05, A10BX02). Duration of treatment was calculated from dates of claimed prescriptions and the dispensed quantity of insulin agents (international units (IU)) and number and strength of tablets for oral glucose-lowering agents, respectively. Individual doses (and thus duration of treatment) were calculated by consideration of up to seven consecutive prescriptions and a continuous treatment period was assumed if this was compatible with at least the minimal daily dose (1 IU for insulin agents and 0.5 tablet of oral glucose-lowering agent), as done previously.\textsuperscript{13–15} For the present study, individuals were classified as exposed between the first claimed prescription and until estimated duration of last claimed prescription.

**Comorbidity**

Charlson comorbidity index was used for adjustment of comorbidity in all analyses.\textsuperscript{16} The index was calculated after time had been split (see Methods section for description) using the left end point as reference. All diagnoses within 10 years prior to the left end point were considered (diabetes and cancer-related diagnoses not included).

**Outcomes**

The end point was any incident cancer reported in the Danish National Hospitalisation Register between 1998 and 2009 (ICD-10 codes C01–C99). Individuals were censored at time of first cancer, death or at the end of 2009. To explore whether distribution of cancers differed according to exposure to individual insulin agents, the following selected groups of cancers (according to ICD-10 codes) were identified: gastrointestinal cancers (C15–C25), lung cancer (C34), prostate cancer (C61), breast cancer (C50), gynaecological cancers (C51–C57) and urological cancers (C64–C67). It should be noted that Denmark possesses a specific national cancer register, in which additional information on, for example, tumour stages is available. The cancer register is mainly based on the national patient register, but some of the diagnoses are manually reviewed in the cancer register, resulting in a discard of a minor part of the cancer diagnoses from the national patient register. For the present analyses, the national patient register was nevertheless considered sufficient in order to investigate the aims of the present paper. We did compare our
end points with the diagnoses in the cancer register (we had data available for 1998–2006 from this latter register) and found a concordance rate exceeding 90%.

**Statistics**

The RR of cancer as dependent on use and duration of individual glucose-lowering pharmacotherapy was examined with multivariable Poisson regression models. The whole cohort was included on 1 January 1998 or at their 35th birthday if younger than 35 years at 1 January 1998.

The lexis-macro (http://192.38.117.59/∼bcz/Lexis/Lexis.sas; last accessed 8 January 2012) was used for all analyses and included two time scales: calendar time (bands were split in 1-year periods after 1 January 1998) and duration of glucose-lowering treatment (bands were split at every change in glucose-lowering treatment regimens as well at 1, 3, 6, 12 months and every year hereafter). Dichotomous variables were hereafter created for the use of glucose-lowering agents (current use or no use; left end point as reference). Similarly, dichotomous variables were created for use of glucose-lowering agents in specific time intervals (eg, ‘use of actrapid day 0–30’ yes vs no; left end point as reference).

Age and comorbidity scores were calculated at the beginning of each interval. For adjustment for the effects of age in Poisson analyses, age was round in 0.5-year intervals.

Two different multivariable Poisson analyses (both being adjusted for Charlson comorbidity score, gender, age and calendar year) were performed. In the first analysis, RRs associated with current use of the different glucose-lowering agents were explored. In the second analysis, the importance of time since initiation of the different agents was explored (variables were included as use vs no use of a specific agent in a specific time window (eg, ‘actrapid day 0–30’, ‘humalog day 365.25–730.5’ etc)).

Calculations were performed using SAS V.9.2 (SAS institute).

**RESULTS**

Of totally 3 607 798 individuals included, 159 894 initiated treatment with glucose-lowering agents. Table 1 presents total numbers of individuals ever exposed and the cumulative exposure time for individual glucose-lowering agents. The most frequently used agents included human insulin and oral glucose-lowering agents. Insulin lispro had a low numbers of users and contributed only with a low cumulative exposure time.

**RR of cancer**

Crude incidence rates, numbers and cancer types are shown in table 1. The distributions of cancer types were similar within the different exposure groups and in the unexposed population group. In multivariable analysis, male gender, increasing age (up to 85 years) and increasing Charlson comorbidity scores were found to be associated with an increased risk of cancer. Figure 1 presents the rate ratio (RR) of cancer associated with use of individual glucose-lowering agents. Besides metformin, most agents were associated with a significant increase in RR compared with the background population. Pooling all insulin analogues into one group and all human insulin agents into another group gave similar results: RR of cancer for use of human insulin was 1.40 (95% CI 1.33 to 1.48) and for use of insulin analogues, it was 1.14 (1.05 to 1.23). As illustrated in figure 2A–C, there was a significant fluctuation in RR of cancer over time. The first 30-day period after initiation of glucose-lowering treatment was associated with a very pronounced increase in RR of cancer for most agents, which subsequently declined rapidly during the first year of treatment, resulting in a RR of 1 after approximately a half to 1 year of treatment.

**DISCUSSION**

In the present nationwide study including more than 3.5 million unselected individuals aged ≥35 years who were naive to glucose-lowering pharmacotherapy at study baseline, we found that use of several different types of glucose-lowering agents, including use of the oral glucose-lowering agent group SU, were associated with an increase in RR of all types of cancer of approximately 20%–30%. Importantly, this risk was found to be highly fluctuating over time with, for example, more than a twofold increase in RR of cancer already during the first 30 days after treatment initiation with insulin. Interestingly, the RR of being diagnosed with cancer declined significantly within the first year after onset of treatment down to that of the background population for all the studied agents. Data from the present nationwide study therefore suggest that the previously reported associations between an increase in risk of cancer and use of insulin are most likely to be driven by confounding and/or surveillance bias.

From the present study, it was impossible to investigate what may have caused the findings, but it is known that hyperglycaemia and cancer are more commonly seen together than expected by chance. In our study population, initiation and use of glucose-lowering therapy may have mirrored poor glycaemic control, occult cancer or both. Hyperglycaemia has previously been shown to increase the risk of several cancer types. Elevated stress levels, as seen in many cancer types, are associated with increasingly fasting serum glucose levels, and patients with cancer are often insulin resistant, which may unmask overt diabetes in predisposed individuals. The immediate risk of cancer on start of insulin therapy is therefore likely to be driven by diagnostic investigation when one of the diagnoses was made. A true risk of cancer caused by insulin therapy would be expected to remain high or even increase over time.

The present study lacked data on several important variables such as body mass index, HbA1c concentrations,
Table 1  Numbers and characteristics of individuals using glucose-lowering agents

| Type of insulin          | Cumulative exposure time (person-years) | N, proportion of male gender (%) | Numbers of cancers | Crude incidence rate (n/1000 person-years) | Age (±SE) (years) | Average Charlson comorbidity score |
|--------------------------|----------------------------------------|---------------------------------|--------------------|--------------------------------------------|------------------|-----------------------------------|
| Actrapid (rapid acting)  | Human insulin 20 147                    | 7606 (58%)                      | 250                | 12.4 (11.6–13.2)                           | 54.4 (±16.1)     | 0.49 (±0.94)                      |
| Mixtard (middle-term acting) | Human insulin 19 827                   | 7288 (54%)                      | 432                | 21.8 (20.7–22.8)                           | 60.6 (±12.7)     | 0.52 (±0.91)                      |
| Insulatard (long-term acting) | Human insulin 70 970                   | 22 078 (58%)                    | 1205               | 17.0 (16.5–17.5)                           | 58.6 (±14.7)     | 0.40 (±0.81)                      |
| Novomix (middle-term acting) | Insulin aspart 24 286                  | 11 740 (60%)                    | 461                | 19.0 (18.1–19.9)                           | 61.0 (±12.4)     | 0.42 (±0.84)                      |
| Novorapid (rapid acting) | Insulin aspart 14 874                  | 5133 (60%)                      | 137                | 9.2 (8.4–10.0)                             | 51.0 (±12.0)     | 0.25 (±0.67)                      |
| Humalog Mix (middle-term acting) | Insulin lispro 465                   | 154 (61%)                       | 5                  | 10.8 (5.9–15.6)                            | 58.8 (±12.2)     | 0.38 (±0.72)                      |
| Humalog (long-term acting) | Insulin lispro 1127                   | 3 447 904 (49%)                 | 293 878            | 7.9 (7.8–7.9)                              | 48.5 (±18.7)     | 0.08 (±0.35)                      |
| Lantus (long-term acting) | Insulin glargine 4483                 | 18.4 (18.1–18.6)                | 63.60 (±13.2)      | 0.27 (±0.67)                               | 60.4 (±12.7)     | 0.20 (±0.52)                      |
| Metformin                 | Insulin detemir 6378                   | 14.3 (14.1–14.5)                | 54.50 (±12.2)      | 0.27 (±0.67)                               | 60.4 (±12.7)     | 0.20 (±0.52)                      |
| Sulfonylureas             | Insulin lispro 557                     | 3 447 904 (49%)                 | 293 878            | 7.9 (7.8–7.9)                              | 48.5 (±18.7)     | 0.08 (±0.35)                      |
| Unexposed population     | Insulin lispro 1127                   | 3 447 904 (49%)                 | 293 878            | 7.9 (7.8–7.9)                              | 48.5 (±18.7)     | 0.08 (±0.35)                      |

Groups are non-exclusive, that is, individuals may contribute to more than one group (except for ‘unexposed population’, which includes only those who did not initiate treatment with glucose-lowering agents or were censored prior to first claimed prescription; individuals from the other groups, however, contributed with exposure time prior to initiation with their first glucose-lowering agent). Mean age and Charlson comorbidity score were calculated as per the date of treatment initiation. For the unexposed group, numbers were calculated as per the calendar time corresponding to half of the length of follow-up.

Andersson C, Vrang A, Selmer C, et al. BMJ Open 2012;2:e000433. doi:10.1136/bmjopen-2011-000433 on June 16, 2022 by guest. Protected by copyright.
physical activity, family cancer history, alcohol consumption, dietary pattern and smoking habits, and it was not
designed or powered to answer questions about the risk
different cancer subtypes or about the safety profiles of individual insulin analogues. As for the risk of specific
cancers with glucose-lowering treatments, it must be emphasised that the pattern of cancer subtypes was
similar within all treatment subgroups and the control
group who were not on any glucose-lowering therapy.
Thus, even though we cannot exclude having overlooked associations between treatments and risk of any
cancer subtypes, it seems unlikely that any quantitative
major causal associations have been overlooked. Of
particular relevance, the previously raised concerns
about the risk associated with use of insulin glargine
could not be thoroughly investigated in the present
study because we had rather few individuals using this
agent and very few patients using glargine developed
cancers, as compared with previous studies. Furthermore, patients were only considered at risk, while
using a specific agent meaning that cancers occurring
after treatment cessation with a specific agent may be overlooked. Nevertheless, it is interesting to speculate
whether and the extent to which the time from initiation
glucose-lowering treatment may have biased the
findings of previous studies. At least when considering
the time of the observation period, insulin glargine
was—and to some extent still is—a relatively new agent
on the market, and it is likely that patients with new-onset diabetes were more prone to initiate treatment
with insulin glargine compared with patients being well
regulated on older agents. In this context, a Swedish
study did not exclude patients with prior use of insulin,
and during a short follow-up time of maximally 2 years,
they found that use of insulin glargine as monotherapy
was associated with a twofold increase in the risk of
breast cancer as compared with use of other types of
insulin. A German study had a significantly longer follow-up time for patients on human insulin
than for patients on insulin glargine, which may have
contributed to their findings of an increased risk of
cancer associated with insulin glargine. In a third
Scottish study investigating the risk of cancer as depen-
dent on insulin glargine, on the other hand, three
specific exposure groups were identified: insulin glar-
gine monotherapy, insulin glargine + non-glargine
insulin and non-glargin insulin monotherapy. Compared with the other two groups, the insulin glar-
gine monotherapy group had significantly shorter
treatment duration prior to study start. The study
demonstrated no excess increase in risk of cancer for the
use of insulin glargine, but when restricting the analysis
to patients on insulin glargine as monotherapy, these
patients were found to have a higher RR of all cancers as

Figure 1  RR of cancer according to exposure to individual glucose-lowering agents.

Figure 2  RR of cancer according to exposure length of individual glucose-lowering agents: (A) human insulin; (B) insulin
analogues; (C) oral agents.
well as breast cancers compared with patients on non-

glargin insulin. The authors concluded that their

finding may be due to allocation bias rather than an
effect of insulin glargin itself, which our data support.

Altogether, more studies are needed to answer this
question, and in particular, our results demonstrate

that it is of crucial importance to take treatment duration

into account, in order to eliminate confounding-by-

indication/surveillance bias.

As also shown in at least one previous study, another

interesting finding of this study was that use of SU was

associated with a risk of cancer quantitatively similar to

that of insulin in overall analysis. While it theoretically
could be speculated that the effect of SU’s to increase
insulin levels in plasma could represent a causal mech-
anism, the finding that this excess risk diminished with
duration of treatment, mirroring the relationship
between insulin and cancer, makes this highly unlikely to
be the case. Indeed, this finding is fully in agreement with
the idea that newly diagnosed diabetes patient are
more often to be diagnosed as having cancer, and vice
versa, all together supporting that the association
between glucose-lowering agents and cancer at least to
some significant extent may represent confounding.

Finally, very recent data from the Food and Drug
Administration side effect registry reported increased
risk of some types of cancer in patients treated for rela-

tively short periods with the novel glucagon-like peptide
(GLP)-based therapies. The current data raise the

possibility that confounding and lack of correction for
time of treatments to some unknown extent may explain

the risk of cancers associated with GLP-1-based thera-
pies.

CONCLUSIONS

Use of most glucose-lowering agents including insulin
was associated with an overall increased risk of cancer.
However, this increase was due to an association
observed earlier in treatment only, suggesting that the
association may not be causal. More studies are
warranted to further investigate this hypothesis.

Acknowledgements

The authors would like to thank Thomas Alexander
Gerds, Dr rer. nat, Department of Public Health, Section of biostatistics,
Copenhagen University, for statistical advises throughout the revision
process of the paper.

Contributors

All authors contributed to conception and design. C.A. and C. T.-P. performed the data analyses. C.A. and C.T.-P. had full access to all of the
data in the study and take responsibility for the integrity of the data and the
accuracy of the data analysis. C.A., A.V. and C.T.-P. drafted the article and all
authors revised it critically for important intellectual content (C.A., A.V., C.S.,
M.S., R.S., J.L., S.H.G., L.K. and C.T.-P.). All authors approved the final
version to be published.

Funding

This research received no specific grant from any funding agency in the
public, commercial or not-for-profit sectors.

Competing interests

All authors report no potential conflicts of interest, but it

should be mentioned that Dr AV was previously employed by Steno Diabetes
Center, which is owned by Novo Nordisk.

Provenance and peer review

Not commissioned; externally peer reviewed.

Data sharing statement

Unfortunately not doable.

REFERENCES

1. Colhoun HM; SDRN Epidemiology Group. Use of insulin glargine and
cancer incidence in Scotland: a study from the Scottish diabetes
research Network Epidemiology group. Diabetologia 2009;52:1755–65.
2. Macalay VM. Insulin-like growth factors and cancer. Br J Cancer
1992;65:311–20.
3. Samani AA, Yakar S, LeRoith D, et al. The role of the IGF system in
cancer growth and metastasis: overview and recent insights. Endocr
Rev 2007;28:20–47.
4. Kurtzhals P, Schaffer L, Sorensen A, et al. Correlations of receptor
binding and metabolic and mitogenic properties of insulin analogs
designed for clinical use. Diabetes 2000;49:999–1005.
5. Smith U, Gale EA. Does diabetes therapy influence the risk of
cancer? Diabetologia 2009;52:1699–708.
6. Weinstein D, Simon M, Yechzekel E, et al. Insulin analogues display
IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells.
Diabetes Metab Res Rev 2009;25:41–9.
7. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer:
a consensus report. CA Cancer J Clin 2010;60:207–21.
8. Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in
patients with diabetes treated with human insulin or insulin analogues:
a cohort study, Diabetologia 2009;52:1732–44.
9. Jonasson JM, Ljung R, Talback M, et al. Insulin glargine use and
short-term incidence of malignancies—a population-based follow-up
study in Sweden. Diabetes Metab 2009;52:1745–54.
10. Marfil A, Sanders RA, Watkins JB 3rd. Diabetes, oxidative
stress, and antioxidants: a review. J Biochem Mol Toxicol 2003;17:24–36.
11. Carlsen B, Witte DR, Friis S. Cancer occurrence in Danish
diabetic patients: duration and insulin effects. Diabetologia
2012;55:948–58.
12. Gaist D, Sorensen HT, Hallas J. The Danish prescription registries.
Dan Med Bull 2003;50:445–8.
13. Andersson C, Olesen JB, Hansen PR, et al. Metformin treatment is
associated with a low risk of mortality in diabetic patients with heart
failure: a retrospective nationwide cohort study. Diabetologia
2010;53:2546–53.
14. Sorensen R, Hansen ML, Abildstrom SZ, et al. Risk of bleeding in
patients with acute myocardial infarction treated with different
times of aspirin, clopidogrel, and vitamin K antagonists in
Denmark: a retrospective analysis of nationwide registry data. Lancet
2009;374:1967–74.
15. Fosbol EL, Gislason GH, Jacobsen S, et al. Risk of myocardial
infarction and death associated with the use of nonsteroidal anti-
inflammatory drugs (NSAIDs) among healthy individuals: a
nationwide cohort study. Clin Pharmacol Ther 2009;85:190–7.
16. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying
prognostic comorbidity in longitudinal studies: development and
validation. J Chronic Dis 1987;40:373–83.
17. Jee SH, Ohr H, Sull JW, et al. Fasting serum glucose level and
cancer risk in Korean Men and Women. JAMA 2005;293:194–202.
18. Statin P, Björ O, Ferrari P, et al. Prospective study of hyperglycemia
and cancer risk. Diabetes care 2007;30:561–7.
19. Halter JB, Beard JC, Porte D Jr. Islet function and stress
hyperglycemia: plasma glucose and epinephrine interaction. Am J
Physiol 1984;247:E47–52.
20. Poulsen J. The management of diabetes in patients with advanced
cancer. J Pain Symptom Manage 1997;13:339–46.
21. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering
therapies on cancer risk in type 2 diabetes. Diabetologia
2009;52:1766–77.
22. Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic,
and thyroid cancer with glucagon-like peptide-1-based therapies.
Gastroenterology 2011;141:150–6.